Abstract
A growing body of research is currently focused on the role of inositol isomers and in particular myo-inositol (MYO-INS) and D-chiroinositol (DCI) in the treatment of insulin resistance states. Both isomers have been shown to exert insulin-mimetic action and to lower postprandial glucose. Further, insulin resistance-related diseases were associated to derangements in inositol metabolism. Thus, the aim of this review is to provide current evidence on the potential benefits of inositol isomers (MYO-INS and DCI) in the treatment of disease associated to insulin resistance such as polycystic ovary syndrome (PCOS), gestational diabetes, and metabolic syndrome. Finally, molecular insights into inositol insulin-sensitizing effects will be covered focusing on the possible role of inositol glycans as insulin second messengers.
| Original language | English |
|---|---|
| Article number | 3058393 |
| Journal | International Journal of Endocrinology |
| Volume | 2016 |
| DOIs | |
| Publication status | Published - 2016 |
Fingerprint
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Endocrinology
- Endocrine and Autonomic Systems
Cite this
Inositols in the Treatment of Insulin-Mediated Diseases. / Muscogiuri, Giovanna; Palomba, Stefano; Laganà, Antonio Simone; Orio, Francesco.
In: International Journal of Endocrinology, Vol. 2016, 3058393, 2016.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Inositols in the Treatment of Insulin-Mediated Diseases
AU - Muscogiuri, Giovanna
AU - Palomba, Stefano
AU - Laganà, Antonio Simone
AU - Orio, Francesco
PY - 2016
Y1 - 2016
N2 - A growing body of research is currently focused on the role of inositol isomers and in particular myo-inositol (MYO-INS) and D-chiroinositol (DCI) in the treatment of insulin resistance states. Both isomers have been shown to exert insulin-mimetic action and to lower postprandial glucose. Further, insulin resistance-related diseases were associated to derangements in inositol metabolism. Thus, the aim of this review is to provide current evidence on the potential benefits of inositol isomers (MYO-INS and DCI) in the treatment of disease associated to insulin resistance such as polycystic ovary syndrome (PCOS), gestational diabetes, and metabolic syndrome. Finally, molecular insights into inositol insulin-sensitizing effects will be covered focusing on the possible role of inositol glycans as insulin second messengers.
AB - A growing body of research is currently focused on the role of inositol isomers and in particular myo-inositol (MYO-INS) and D-chiroinositol (DCI) in the treatment of insulin resistance states. Both isomers have been shown to exert insulin-mimetic action and to lower postprandial glucose. Further, insulin resistance-related diseases were associated to derangements in inositol metabolism. Thus, the aim of this review is to provide current evidence on the potential benefits of inositol isomers (MYO-INS and DCI) in the treatment of disease associated to insulin resistance such as polycystic ovary syndrome (PCOS), gestational diabetes, and metabolic syndrome. Finally, molecular insights into inositol insulin-sensitizing effects will be covered focusing on the possible role of inositol glycans as insulin second messengers.
UR - http://www.scopus.com/inward/record.url?scp=84988944609&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84988944609&partnerID=8YFLogxK
U2 - 10.1155/2016/3058393
DO - 10.1155/2016/3058393
M3 - Review article
AN - SCOPUS:84988944609
VL - 2016
JO - International Journal of Endocrinology
JF - International Journal of Endocrinology
SN - 1687-8337
M1 - 3058393
ER -